2018 IMPAACT Annual Meeting Tuberculosis Scientific Committee Presentations

Anneke Hesseling and Amita Gupta

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIVUninfected Infants, Children and Adolescents with MDR-TB Disease	Anneke Hesseling
IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB	Ethel Weld
IMPAACT 2020: Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial	Anthony Garcia-Prats
Drug Susceptible TB: Opportunities and Priorities	Tuberculosis Scientific Committee

Update and Way Forward for Phase I/II Maternal and Pediatric Prevention Studies: P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-infected Women in High TB Incidence Settings A5279: One month of Rifapentine/Isoniazid to Prevent TB in People with HIV: BRIEF-TB	Amita Gupta
IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection	Jyoti Mathad
P1026s: Pharmacokinetic Properties of Antiretroviral Therapy during Pregnancy	Jennifer Hughes
TB Pregnancy Registry	Tuberculosis Scientific Committee

Innovative statistical methods for Phase III Tuberculosis Trials in Children	Soyeon Kim
State of the Art: TB drug pharmacokinetics at the site of disease	Veronique Dartois
Regulatory Perspectives from the FDA on Priorities and Methods for TB Trials in Children and Pregnant Women	Lynne Yao
Roundtable Discussion: Future MDR-TB Trials	Tuberculosis Scientific Committee